Our flagship product is now approved by the U.S. FDA for the treatment of patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible.
Company Statement on COVID-19
Exelixis is actively monitoring the global COVID-19 pandemic, and remains steadfast in our commitment to the health and safety of our patients, customers, employees and local communities.
25 Years Resilient Together
Learn more about our journey of progress for
patients and our efforts to translate drug discovery
and development into breakthrough medicines.
Cancer is our Cause
We strive to develop effective, tolerable and durable
treatments to help patients with cancer thrive.
Tackling Difficult-to-Treat Cancers
To date, we have three medicines available to treat certain types of kidney, liver and thyroid cancers and advanced melanoma.
At Exelixis, everyone leads in our collective quest to drive for results so patients can have hope for remission.